Lupin three senior executives to retire in 2 days

Mumbai: Global pharmaceutical giant Lupin has announced the retirement of its three senior executives.

Naresh Gupta, President – API Plus & GTB, Sunil Makharia, President – Finance, and Rajender Kamboj, President – Novel Drug Discovery & Development, part of the Senior Management of the Company, shall retire from their positions at the close of business hours on March 31, 2025.

Lupin has not yet announced their successors.

Naresh has been associated with Lupin for over 32 years. Naresh is also associated with Confederation of Indian Industry (CII) and the Federation of Indian Chambers of Commerce & Industry (FICCI). Additionally, He has been the Vice President of the Bulk Drug Manufacturers’ Association of India. Naresh holds an M.Phil. and a degree in management studies from the Institute of Management Studies, Shimla.

Sunil Makharia is a seasoned finance leader with three decades of experience. Prior to Lupin, he has held senior positions in finance and general management at companies such as Grasim and Indian Tools. Sunil is a qualified chartered accountant and has a management degree from the Indian School of Business, Hyderabad.

Raj Kamboj has expertise spanning drug discovery, technology licensing, business development, M&A, research and corporate development. Prior to Lupin, he has worked with Xenon Pharmaceuticals and NPS Allelix, Canada. Raj has over 200 US patents and has authored and co-authored over 90 research articles on biomedical. He earned his doctorate from the University of Adelaide, Australia.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.

Read also: Lupin Digital Health introduces Post-Procedure Home-Based Care Guide